Drugs / Sonesitatug Vedotin
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04805307 | Dec 2020 → Apr 2024 | gastric carcinoma, malignant pancreatic neoplasm | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07143604 | Aug 2025 → Sep 2026 expected | gastric cancer, gastroesophageal junction adenocarcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07069712 | Jul 2025 → Jan 2027 expected | gastroesophageal adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT06630130 | Jan 2025 → Oct 2028 expected | gastric cancer | Jeeyun Lee | Recruiting | No outcome recorded |
| Phase 2 | NCT06219941 | Dec 2023 → Aug 2026 overdue | biliary tract cancer, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT05702229 | Jan 2023 → Nov 2027 expected | gastric cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07431281 | Feb 2026 → Aug 2029 expected | esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06346392 | Mar 2024 → May 2026 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | AstraZeneca | Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers astrazeneca.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sonesitatug vedotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07431281 ↗ |
| Known as | AZD0901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06346392 ↗ |
| Known as | CMG901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04805307 ↗ |
| Known as | Sone-Ve | “Sonesitatug Vedotin(Sone-Ve) 2.2mg /kg IV on D1, Q3W for 3 cycles” NCT06630130 ↗ |
| Known as | Sonesitatug vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068297 ↗ |
| Known as | Sonesitatug vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068297 ↗ |
| Modality | Other / unclassified | “an anti Claudin18.2 ADC; IV infusion” NCT05702229 ↗ |
| Route | Intravenous | “CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle.” NCT04805307 ↗ |
| Target | CLDN18 | “Claudin 18.2-targeting antibody-drug conjugate CMG901” PMID 39788133 ↗ Jan 2025 |